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Summary.-This paper compares anti-leukaemic efficiency with toxicity to the
patient of chemotherapy during and immediately after central nervous system
irradiation. The drug regimen consisted of daily mercaptopurine (MP) and weekly
methotrexate (MTX) at the maximum tolerated dose. Of 140 patients with acute
lymphoblastic leukaemia allocated to receive this drug regimen during and after
cranial irradiation, 8 died in complete remission within 6 months of the end of
irradiation. Details ofthe nature ofthese deaths are given. This result led the Working
Party to modify the chemotherapy scheduled for this stage in treatment. The modi-
fied chemotherapy consisted of MP at reduced dosage before and during cranial
irradiation and omission of MP and MTX for 3 weeks after irradiation, during which
time daily prednisolone with 2 doses of vincristine were substituted. Following
that, the treatment reverted to the original schedule of daily MP and weekly MTX
at maximum tolerated dose. Of 109 patients allocated to this modified regimen
only one died in remission within 24 weeks after cranial irradiation. Analysis of the
anti-leukaemic effect of the modified regimen showed that up to 600 days it was
at least as effective as the original more intensive regimen. We conclude that there is a definite advantage in keeping chemotherapy to a minimum during and immedi-
ately following cranial prophylactic irradiation.
WHILE there have been marked im-
provements in the treatment of acute
lymphoblastic leukaemia, the risk of
serious infection in patients who have
already achieved complete remission has
become a matter for concern. Such infec-
tions are most often seen in patients
who at diagnosis have leucocyte counts
below 20 x 109/1 and are less than 14
years old; they comprise about 6000
of all ALL patients and otherwise have
a good prognosis (MRC Working Party,
1976). We have previously shown that
the degree of myelotoxocity and immuno-
suppression can be markedly altered by
relatively small changes in drug schedules
(MRC Working Party, 1975, 1976) or
central nervous system (CNS) irradiation
(MRC Working Party, 1977).
In this paper we report our experience
of a treatment protocol, UKALL III
ordinary, which was designed for patients
with acute lymphoblastic leukaemia with
good prognostic features. Several patientsUKALL I CNS IRRADIATION (a)
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FIG. 1.-Treatment protocols in UKALL trials. MP = 6 mercaptopurine; MTX = methotrexate;
VCR = vincristine; CA = cytosine arabinoside; CYCLO = cyclophosphamide; ASN'ASE = as-
paraginase; PRED = prednisolone; i.v. = intravenous; i.m. = intramuscular; 0 = oral; IT
intrathecal; d = day.
(a) UKALL I. 54 patients. CNS prophylaxis was the variable tested in this trial. Only those
patients receiving CNS prophylaxis are included in the analysis. Intrathecal MTX was given on
the first day of each of the 11 MTX courses between Weeks 17 and 55. No systemic MTX was
given on those days. The oral methotrexate courses in Weeks 15 and 17 were of 3 and 4 daily
doses respectively, thereafter all courses were of 5 daily doses. CNS irradiation consisted of a total
mid-line dose of 2500 rad to the cranium given by opposing lateral fields, and 1000 rad to the
spine measured at the posterior surface of the vertebral bodies. Further details are given in: MRC
Working Party (1973).
(b) UKALL II. 174 patients. The randomized variables analysed were type of CNS irradiation
and cyclophosphamide. All patients who achieved remission and who received CNS irradiation are
included in this study. All patients received irradiation as a total mid-line dose of2400 rad given by
opposing lateral fields. Of the three CNS prophylaxis groups: (1) received no spinal irradiation
but intrathecal MTX as indicated; (2) received 1000 rad to the spine as in UKALL I and intra-
thecal MTX; (3) received 2400 rad to the spine but no intrathecal MTX. Groups 2 and 3 were
randomized to receive cyclophosphamide or not, but all patients in Group 1 received cyclophos-
phamide. Half the patients stopped chemotherapy after Week 108; the remainder stopped after
Week 156. Further details: MRC Working Party (1976).
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(c) Original UKALL III ordinary. 140 patients. Patients randomized to one of 4 groups: A-received asparaginase 1 only and no cytosine arabinoside. MTX was not interrupted. B-re- ceived asparaginase II each module and no cytosine arabinoside. MTX was not interrupted. C-received asparaginase I only with cytosine arabinoside each module replacing MTX for 2 weeks. D-received asparaginase II each module with cytosine arabinoside each module replacing MTX for 2 weeks. Cranial irradiation as Group 1 UKALL II
(d) Modified UKALL III ordinary. 109 patients analysed. Patients were randomized to one of two groups. A-continuous MP after Week 12. E MP interrupted in Week 11, 15, 19 etc. Cranial irradiation as Group 1 UKALL II.
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died in complete remission during the
first few weeks after CNS irradiation.
Deaths had not occurred at this stage
in earlier UKALL trials. AVe analyse
here the reasons for these early deaths
and show how a minor modification of
the UKALL III ordinary protocol reduced
the associated early toxicity without
apparent loss of anti-leukaemic efficiency.
PATIENTS
The patients were all entered to the
British Medical Research Council's multi-
centre UKALL trials. The protocols used
are: UKALL I CNS irradiation group (Fig.
la); UKALL II all groups (Fig. Ib): the
original UKALL III ordinary all groups
(Fig. Ic); and the modified UKALL III
ordinary both groups (Fig. Id). Details are
given in the legends to Fig. 1.
Patients were allocated to UKALL III
ordinary only ifthey had a "good prognosis",
(i.e. they were less than 14 years old, pre-
sented with a white-cell count of less than
20 x 109/1 and had no radiographic evidence
-r - 1 - 4 - - --I - 1 - _ d4 \ f - --4 -& 01 meuiastiniai enlargement). '
fulfilling these criteria are analy
The entry to the three trials ,"
Weeks from entry to trial
10 20 30 40 50 60 70 80 90 100 110 120 130 140 150
.--..
0 _ _ 1 year follow up only
FIG. 2. Deaths in remission
prognosis patients who recei'
prophylaxis. * = one death. 0
randomized to UKALL III moc
received chemotherapy similar t(
III original (see text). Number c
at risk:
UKALL I CNS irradiatioin gioup
UKALL II all groups
Original UKALL III ordinary
Modified UKALL III orclinary
(Details of UKALL I and II
deaths are reported in MRC
Party, 1975 and 1976 resr UKALL III modified is foll
to 31.12.1976 (i.e. only one y last patient entered the trial).
as indicated in Figures la-d, and ran from
September 1970 to October 1975. All patients
in these trials who achieved remission and
completed CNS irradiation, are included in
the life-table analysis, irrespective of devia-
tions. For this reason the number of patients
in UKALL II is greater than that reported
previously (MRC Working Party, 1976).
We have examined the treatment given to
all patients who died in remission and
indicate where significant deviations occurred.
METHODS
All data wvere recorded at the individual
treatment centres on standard record cards
which were analysed at the Leukaemia
Trials Office in London. Life tables are
drawn by the Surv-C programme package
(Peto et al., 1976, 1977). For reasons of
clarity the minimum percentage drop in the
life-table plots is 2%.
RESULTS
Early rentission deaths in patients on the
original UKALL III ordinary regimen
iniy patients Eight out of the 140 patients who had
sed. completed CNS irradiation died in com-
Tas sequential plete remission before the end of the
second 12-week post-irradiation treat-
ment module (i.e. Week 34). The clinical
details of these patients are summarized
in the Table, together with remission
UKALL m original deaths occurring later. By the beginning
UKALL rn modified of November 1974 5 of the 8 early re-
mission deaths had already been reported
UKALL I to the Leukaemia Trials Office. It was
then decided to modify the protocol for
the following reasons:
in good- (a) The high incidence ofearlyremission
patieCNt deaths is not an inevitable consequence
lified who of CNS irradiation, for only one remission
o UKALL death had occurred in the 6 months if patients following CNS irradiation in the group
only 54 of 228 good-prognosis patients at risk 174 in UKALL I and II. The children in
140 these earlier trials had been irradiated
remission at the same centres, generally using the
Working same techniques. Fig. 2 compares the pectively.) stages at which remission deaths occurred
[owea up in good-prognosis patients in the different
UKALL trials.
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Fie. :3. Life tables in which UKALL III
or(linary, mo(lifie(1 (109 patients, (lashe(l
line) and original (140 patients, con-
tinuous line) are comparedc (a) for disease-
free survival and (b) for remission length
censoring at death in remission (i.e.
treating as withdrawn at (leath in re-
mission). For interpretation see text.
(b) Although some of these fatal infec-
tions were due to epidemic illnesses,
their variety was too great to make it
likely that only abnormal environmental
factors were responsible. However, there
is a suggestion of a seasonal incidence for
the deaths in this trial (Table). All the
1]3 fatal infections occurred between
September and April, none in the months
from May to August.
Only two of the remission deaths in
patients on this protocol are linked by
the nature of infecting organism as well
as time of death and treatment centre.
These are Cases 5 and 6 in the Table.
Three other pairs, 10 and 12, 7 and 9,
and 2 and 8 were treated at the same
centre but only in Case 8, one of 3 closely-
linked cases of measles pneumonia (Shah
et al., 1977), was there evidence ofpossible
cross-infection.
(c) Comparison of the chemotherapy
regimen in UKALL III with earlier
trials showed the following differences.
The maximum daily dose of MP during
CNS irradiation was increased from 35
mg/M2 (UKALL II) to 75 mg/M2 in the
original UKALL III ordinary regimen.
In UKALL I and II only vincristine
and prednisolone had been given in the
first 3 weeks after irradiation, but in
the original UKALL III ordinary, over
this period up to 75 mg MP/m2 was also
given each day and 15 mg of MTX/m2
on the first day of each of these weeks.
It should be noted that most of the
patients who died in remission never
received this maximum daily dose of
MP (Table) (but patient 4 exceeded it by
receiving 90-135 mg/M2).
Modification to UKALL III ordinary
As the result of these findings entry
to the original UKALL III ordinary
protocol was stopped on 17. 11 . 74, and
subsequent patients were randomized to
one ofthe two arms of a modified UKALL
III ordinary regimen (Fig. Id). In this,
the maximum daily dose of MP before
and during cranial irradiation was reduced
to 25 mg/M2 and the MP plus MTX
treatment of the first 3 weeks after
irradiation was replaced by vincristine
prednisolone. Amnong the 109 patients
who achieved remission and completed
irradiation after the protocol had been
modified, only one death in remission
occurred within one year of starting
treatment in Week 24. However, that
patient had deviated from the protocol,
having received MP in the first 5 weeks,
with MTX on the 1st, 3rd and 5th weeks
after CNS irradiation. The treatment
given, therefore, was similar to the original
UKALL IlI ordinary regimen. This
patient died from gram-negative septi-
caemia with retroperitoneal haemorrhage;
the neutrophil count was below 0 5 x 109/1
at the onset ofinfection.
Comparison of the anti-leukaemic effect
of original UKALL III ordinary protocol
with the modified regimen and with UKALL
I and II
Fig. 3(a) depicts the disease-free sur-
vival in the original and modified regi-
mens. When remission duration is plotted
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Fic-. 4. Life tables showing disease-free survival (a) and overall survival (b) in UKALL I irradiation
(54 patienits fir), UKALL If all groups (174 patients Ilall), UKALL fII original (40 patients
Tlori) anidl UKALL fI1 modified (109 patients IIlmod). Only good-prognosis patients achieving
remission an(l completintg CNS irra(liation are analyse(l. Figures in brackets indicate number
of patients in each gr'oup at the end of analysis.
censoring patients at death in remission,
the slope of the life-table for remission
in the two regimens is seen to be the
same (Fig. 3b). From these life-tables
it would appear that the anti-leukaemic
efficiency of the original UKALL III
42
ordinary regimen is no better than that
of its modification. However, comparative
analysis of these two regimens only tells
us about events in the first 600 days of
the trial. Survival (Fig. 4a) and disease-
free survival (Fig. 4b) are compared for
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the first 900 days for the original UKALL
III ordinary protocol with UKALL I
CNS irradiation patients and all patients
in UKALL II. The original UKALL III
ordinary protocal has produced worse
results than the other schedules. This
appears to be almost entirely attributable
to its early toxicitv.
DISCUSSION
Irradiation of lymphoid tissue results
in marked lymphopenia. There are two
components to this. One component,
which is rapidly replenished, includes
many cells with surface immunoglobulin
and K cells (Campbell et al., 1976).
The second component largely comprises
lymphocytes which form rosettes with
sheep red cells; this recovers only slowly
if at all (Buckton, Court-Brown and
Smith, 1967; Stjernsward et al., 1972).
It may be that the addition of MP to
the UKALL III original protocol im-
mediately after CNS irradiation critically
delays the recovery of the rapidly re-
populating fraction of lymphocytes de-
stroyed by irradiation. In a previous
paper (Waller et al., 1977) we showed
that MP depressed a small population
oflymphocytes which is rapidly replenish-
ed when this drug is stopped. These
lymphocytes, like the rapidly repopulating
radiation-sensitive pool, include K cells
and many surface-immunoglobulin-posi-
tive cells. In that paper we produced
indirect evidence that this MP-sensitive
population of lymphocytes might be
important as defence against viral infec-
tions. If this is the explanation for the
early deaths, the timing may have been
as important as the total dose of MP in
the early deaths.
Other factors might also have been
important. For example, lung infection
is the most striking common feature
of the early fatal infections, and perhaps
the UKALL III original treatment caused
transient lung damage which predisposed
to a variety of infections. Neutrophils
may also have been prevented from
normal recovery by the UKALL III
therapy, for in all the first 5 cases (Table)
terminal neutropenia was marked. How-
ever, pyogenic infection was not pro-
minent in this series.
It is also possible that lack offamiliarity
with the original UKALL III may have
contributed to theseearlyremissiondeaths,
since 5 occurred in patients admitted in
the first 4 months of the trial and only 3
in the latter 91 months. It is revealing
to read the reports from St Jude, Mem-
phis, where a consistent factor of the
protocols has been the administration
of daily MP 50 mg/M2, and weekly MTX
during and after CNS irradiation (Simone
et al., 1975). The desirability of reducing
doses during irradiation is emphasized
in their report of Protocol V7I (Aur et al.,
1972). They write "Radiotherapy was
administered in full dosage in all but
four patients. All four entered in the
early months of the study. They received
only 700-1200 rad cranio-spinal irradia-
tion because of severe pancytopenia,
fever or infection. In subsequent patients,
continuation chemotherapy was reduced
more readily during radiotherapy, and
this problem was averted."
It seems, therefore, from the Memphis
experience and our own, that intensive
chemotherapy during and immediately
after CNS irradiation is likely to result
in serious infection. Our data indicate
that relatively gentle chemotherapy dur-
ing this period has no disadvantage in
terms of anti-leukaemic effect, while it
is associated with far less toxicity.
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